Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administration of Sugammadex (MK-8616) in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary)
- Indications Neuromuscular blockade
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 01 Oct 2018 Results published in the British Journal of Anaesthesia
- 15 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Mar 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.